The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Self-citationBray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
“160,166,167 Because these cancers often represent a large proportion of all bladder cancers 168 and are commonly associated with reasonably favorable survival, comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.”
BackgroundSelf-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D. M., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. T., ELIAS, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,602
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Cumberbatch, M. G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemeney, L. A. L. M., Lotan, Y., Pang, K. H., Silverman, D. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.001 · Cited by 822
Self-citationŞanlı, Ö., Dobruch, J. T., Knowles, M. A., Burger, M., Mehrdad Alemozaffar, A., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 825
Chen, Z., Zhou, L., Liu, L., Hou, Y., Xiong, M., Yang, Y., Hu, J., & Chen, K. (2020) · Nature Communications · doi:10.1038/s41467-020-18916-5 · Cited by 694
Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R. A., Kennish, S. J., Lerner, S. P., Montironi, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.04.029 · Cited by 663
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Flaig, T. W., Spiess, P. E., Abern, M., Bangs, R., Bangs, R., Begovic, J., Brown, J., Buyyounouski, M. K., Chan, K., Chang, P. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0011 · Cited by 642
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 641
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J. Y., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 612
CircHIPK3 sponges miR‐558 to suppress heparanase expression in bladder cancer cells
Li, Y., Zheng, F., Xiao, X., Xie, F., Tao, D., Huang, C., Liu, D., Wang, M., Wang, L., Zeng, F., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643581 · Cited by 562
Yang, C., Yuan, W., Yang, X. F., Peng, L., Wang, J., Han, J., Tao, J., Li, P., Yang, H., Lv, Q., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0771-7 · Cited by 516
Arsenic exposure: A public health problem leading to several cancers
Lara, I. P., Castillo, M. M., Quintana-Pérez, J. C., Arellano-Mendoza, M. G., Cach, F. T., Valenzuela, O. L., García-Montalvo, E. A., & Hernández‐Zavala, A. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104539 · Cited by 494
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 459
Zhong, Z., Huang, M., Lv, M., He, Y., Duan, C., Zhang, L., & Chen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.027 · Cited by 449
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Compérat, É., Amin, M. B., Cathomas, R. L., Choudhury, A., Santis, M. D., Kamat, A. M., Stenzl, A., Thoeny, H. C., & Witjes, J. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01188-6 · Cited by 460
Bladder Cancer: Current Challenges and Future Directions
Dobruch, J. T., & Oszczudłowski, M. (2021) · Medicina · doi:10.3390/medicina57080749 · Cited by 424
A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer
Wu, S., Zheng, J., Li, Y., Yu, H., Shi, S., Xie, W., Liu, H., Su, Y., Huang, J., & Lin, T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1510 · Cited by 399
van Hoogstraten, L. M. C., Vrieling, A., van der Heijden, A. G., Kogevinas, M., Richters, A., & Kiemeney, L. A. L. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00744-3 · Cited by 404
Epidemiology, Screening, and Prevention of Bladder Cancer
Lobo, N., Afferi, L., Moschini, M., Mostafid, H. A., Porten, S. P., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.10.003 · Cited by 393
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Bellmunt, J., Powles, T., & Vogelzang, N. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.007 · Cited by 374
Global Burden of Urologic Cancers, 1990–2013
Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M., & Fitzmaurice, C. (2016) · European Urology · doi:10.1016/j.eururo.2016.10.008 · Cited by 376
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 391
Progress in cancer mortality, incidence, and survival: a global overview
Santucci, C., Carioli, G., Bertuccio, P., Malvezzi, M., Pastorino, U., Boffetta, P., Negri, E., Bosetti, C., & Vecchia, C. L. (2020) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000594 · Cited by 341
Lu, Q., Liu, T., Feng, H., Yang, R., Zhao, X., Chen, W., Jiang, B., Qin, H., Guo, X., Liu, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1040-0 · Cited by 313
Wong, M. C. S., Fung, F. D. H., Leung, C., Cheung, W. W. L., Goggins, W. B., & Ng, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19199-z · Cited by 308
Lin, T., Zhao, X., Zhao, S., Yu, H., Cao, W., Chen, W., Wei, H., & Guo, H. (2018) · Theranostics · doi:10.7150/thno.22465 · Cited by 307
Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors
Hortelão, A. C., Carrascosa, R., Murillo-Cremaes, N., Patiño, T., & Sánchez, S. (2019) · ACS Nano · doi:10.1021/acsnano.8b06610 · Cited by 287
Bladder Cancer, Version 3.2024
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., Chan, K., Chang, S. S., Chang, P. J., Friedlander, T. W., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0024 · Cited by 286
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio Lopez-beltran, B., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Liang Cheng, C., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 285
Natural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 267
Teoh, J. Y.-C., Huang, J., Ko, W. Y.-K., Lok, V., Choi, P., Ng, C.-F., Sengupta, S., Mostafid, H., Kamat, A. M., Black, P. C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.006 · Cited by 257
The potential role of N7-methylguanosine (m7G) in cancer
Luo, Y., Yao, Y., Wu, P. S., Zi, X., Sun, N., & He, J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01285-5 · Cited by 257
Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
Ceci, C., Lacal, P. M., Tentori, L., Martino, M. G. D., Miano, R., & Graziani, G. (2018) · Nutrients · doi:10.3390/nu10111756 · Cited by 254
Management of metastatic bladder cancer
Nadal, R., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.002 · Cited by 249
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect
Han, J., Gu, X., Li, Y., & Wu, Q. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110393 · Cited by 237
Wang, F., Lin, J., Chen, X., Zhou, X., Zhang, Y., Yu, Y., Fan, M., Cai, Y., Xiang, J., Huang, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01856-1 · Cited by 242
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222
Ni, Z., Sun, P., Zheng, J., Wu, M., Yang, C., Cheng, M., Yin, M., Cui, C., Wang, G., Yuan, L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1323 · Cited by 221
Taber, A., Christensen, E., Lamy, P., Nordentoft, I., Prip, F., Lindskrog, S. V., Birkenkamp‐Demtröder, K., Okholm, T. L. H., Knudsen, M., Pedersen, J. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18640-0 · Cited by 214
Pfannstiel, C., Strissel, P. L., Chiappinelli, K. B., Sikic, D., Wach, S., Wirtz, R. M., Wullweber, A., Taubert, H. W., Breyer, J., Otto, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0758 · Cited by 213
Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions
Yan, M., Wu, S., Wang, Y., Liang, M., Wang, M., Hu, W., Yu, G., Mao, Z., Huang, F., & Zhou, J. (2023) · Advanced Materials · doi:10.1002/adma.202304249 · Cited by 214
Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression
Su, H.-W., Tao, T., Yang, Z., Kang, X., Zhang, X., Kang, D., Wu, S., & Li, C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0951-0 · Cited by 210
Gu, C., Wang, Z., Zhou, N., Li, G., Kou, Y., Luo, Y., Wang, Y., Yang, J., & Tian, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1084-1 · Cited by 205
The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040
Zhang, Y., Rumgay, H., Li, M., Yu, H., Pan, H., & Ni, J. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04109 · Cited by 212
[i]In-vivo[/i] Raman spectroscopy: from basics to applications
Cordero, E., Latka, I., Matthäus, C., Schie, I. W., & Popp, J. (2018) · Journal of Biomedical Optics · doi:10.1117/1.jbo.23.7.071210 · Cited by 196
Jin, H., Ying, X., Que, B., Wang, X., Chao, Y., Zhang, H., Yuan, Z., Qi, D., Lin, S., Wang, M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.068 · Cited by 195
Witjes, J. A., Babjuk, M., Joaquim Bellmunt, B., Bruins, H. M., de Reijke, T. M., Santis, M. D., Gillessen, S., James, N. D., MacLennan, S., Palou, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.035 · Cited by 196
Urease-powered nanobots for radionuclide bladder cancer therapy
Simó, C., Serra-Casablancas, M., Hortelão, A. C., Carlo, V. D., Guallar-Garrido, S., Plaza‐García, S., Rabanal, R. M., Ramos‐Cabrer, P., Yagüe, B., Aguado, L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01577-y · Cited by 202
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
Nieuwenhuizen, N. E., Kulkarni, P. S., Shaligram, U. S., Cotton, M. F., Rentsch, C. A., Eisele, B., Grode, L., & Kaufmann, S. H. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01147 · Cited by 199
METTL1‐m7G‐EGFR/EFEMP1 axis promotes the bladder cancer development
Ying, X., Liu, B., Yuan, Z., Huang, Y., Chen, C., Xu, J., Zhang, H., Qi, D., Yang, S., Lin, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.675 · Cited by 188
Liu, H., Bi, J., Dong, W., Yang, M., Shi, J., Jiang, N., Lin, T., & Huang, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0908-8 · Cited by 185
Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine
Xue, C., Chu, Q., Zheng, Q., Jiang, S., Bao, Z., Su, Y., Lü, J., & Li, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01003-0 · Cited by 192
Trihalomethanes in Drinking Water and Bladder Cancer Burden in the European Union
Evlampidou, I., Font-Ribera, L., Rojas-Rueda, D., Gracia-Lavedan, E., Costet, N., Pearce, N., Vineis, P., Jaakkola, J. J. K., Delloye, F., Makris, K. C., et al. (2020) · Environmental Health Perspectives · doi:10.1289/ehp4495 · Cited by 178
Dong, W., Bi, J., Liu, H., Yan, D., He, Q., Zhou, Q., Wang, Q., Xie, R., Su, Y., Yang, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1025-z · Cited by 180
Arsenic toxicity: sources, pathophysiology and mechanism
Ganie, S. Y., Javaid, D., Hajam, Y. A., & Reshi, M. S. (2023) · Toxicology Research · doi:10.1093/toxres/tfad111 · Cited by 201
Wei, W., Sun, J., Zhang, H., Xiao, X., Huang, C., Wang, L., Zhong, H., Jiang, Y., Zhang, X., & Jiang, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1518 · Cited by 178
Woerl, A.-C., Eckstein, M., Geiger, J., Wagner, D., Daher, T., Stenzel, P., Fernandez, A., Hartmann, A., Wand, M., Roth, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.023 · Cited by 177
Horwich, A., Babjuk, M., Joaquim Bellmunt, B., Bruins, H. M., de Reijke, T. M., Santis, M. D., Gillessen, S., James, N. D., MacLennan, S., Palou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz296 · Cited by 178
European cancer mortality predictions for the year 2020 with a focus on prostate cancer
Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., Vecchia, C. L., Negri, E., & Malvezzi, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.009 · Cited by 171
Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis
Zhang, Y., Luo, G., Li, M., Guo, P., Xiao, Y., Ji, H., & Hao, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-6139-6 · Cited by 169
Wu, S., Zheng, J., Li, Y., Wu, Z., Shi, S., Huang, M. X., Yu, H., Dong, W., Huang, J., & Lin, T. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.029 · Cited by 168
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention
Abbaoui, B., Lucas, C. R., Riedl, K. M., Clinton, S. K., & Mortazavi, A. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800079 · Cited by 168
Katanoda, K., Hori, M., Saito, E., Shibata, A., Ito, Y., Minami, T., Ikeda, S., Suzuki, T., & Matsuda, T. (2021) · Journal of Epidemiology · doi:10.2188/jea.je20200416 · Cited by 164
Emerging function and potential diagnostic value of circular RNAs in cancer
Cui, X., Wang, J., Guo, Z., Li, M., Li, M., Liu, S., Liu, H., Li, W., Yin, X., Tao, J., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0877-y · Cited by 164
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 162
CircRNA-Cdr1as Exerts Anti-Oncogenic Functions in Bladder Cancer by Sponging MicroRNA-135a
Li, P., Yang, X. F., Yuan, W., Yang, C., Zhang, X., Han, J., Wang, J., Deng, X., Yang, H., Li, P., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489208 · Cited by 157
Epidemiology, aetiology and screening of bladder cancer
party, O. B. O. T. E. Y. A. U. C. W., Cumberbatch, M. G. K., & Noon, A. P. (2019) · Translational Andrology and Urology · doi:10.21037/tau.2018.09.11 · Cited by 148
FTO modifies the m6A level of MALAT and promotes bladder cancer progression
Tao, L., Mu, X., Chen, H., Jin, D., Zhang, R., Zhao, Y., Fan, J., Cao, M., & Zhou, Z. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.310 · Cited by 151
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review
Fonteyne, V., Ost, P., Joaquim Bellmunt, B., Droz, J. P., Mongiat-Artus, P., Inman, B. A., Paillaud, É., Fred Saad, C., & Ploussard, G. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.019 · Cited by 145
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
Jiang, D., Gupta, S., Kitchlu, A., Meraz-Muñoz, A., North, S. A., Alimohamed, N. S., Blais, N., & Sridhar, S. S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00404-6 · Cited by 144
Malek-Esfandiari, Z., Rezvani‐Noghani, A., Sohrabi, T., Mokaberi, P., Amiri‐Tehranizadeh, Z., & Chamani, J. (2023) · Journal of Fluorescence · doi:10.1007/s10895-023-03169-4 · Cited by 144
Air pollution exposure and bladder, kidney and urinary tract cancer risk: A systematic review
Sakhvidi, M. J. Z., Lequy, É., Goldberg, M., & Jacquemin, B. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115328 · Cited by 141
Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer
Thomsen, M. B. H., Nordentoft, I., Lamy, P., Vang, S., Reinert, L. S., Mapendano, C. K., Høyer, S., Orntoft, T. F., Jensen, J. B., & Dyrskjøt, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-11291-0 · Cited by 133
The emerging role of circRNAs and their clinical significance in human cancers
Qian, L., Yu, S., Chen, Z., Meng, Z., Huang, S., & Wang, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.002 · Cited by 136
Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis
Liu, F., Zhang, H., Xie, F., Tao, D., Xiao, X., Huang, C., Wang, M., Gu, C., Zhang, X., & Jiang, G. (2019) · Oncogene · doi:10.1038/s41388-019-1092-z · Cited by 135
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Jing, W., Wang, G., Cui, Z., Xiong, G., Jiang, X., Li, Y., Li, W., Han, B., Chen, S., & Shi, B. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2362 · Cited by 135
Zhan, Y., Chen, Z., Li, Y., He, A., He, S., Gong, Y., Li, X., & Zhou, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0921-1 · Cited by 133
Yuan, W., Zhou, R., Wang, J., Han, J., Yang, X. F., Yu, H., Lu, H., Zhang, X., Li, P., Tao, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12523 · Cited by 131
Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles
Ahlawat, J., Henrı́quez, G., & Narayan, M. (2018) · Molecules · doi:10.3390/molecules23092157 · Cited by 131
Soerjomataram, I., Cabasag, C., Bardot, A., Fidler-Benaoudia, M. M., Miranda-Filho, A., Ferlay, J., Parkin, D. M., Ranganathan, R., Piñeros, M., Znaor, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00704-5 · Cited by 128
Self-citationBladder cancer-related microbiota: examining differences in urine and tissue samples
Mansour, B., Monyók, Á., Makra, N., Gajdács, M., Vadnay, I., Ligeti, B., Juhász, J., Szabó, D., & Ostorházi, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-67443-2 · Cited by 128
lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA‐150
Luo, H., Xu, C., Le, W., Ge, B., & Wang, T. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28622 · Cited by 127
The evolving genomic landscape of urothelial carcinoma
Glaser, A. P., Fantini, D., Shilatifard, A., Schaeffer, E. M., & Meeks, J. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.11 · Cited by 126
Zhan, Y., Chen, Z., He, S., Gong, Y., He, A., Li, Y., Zhang, L., Zhang, X., Fang, D., Li, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1143-7 · Cited by 126
Liu, Z., Zhou, Q., Wang, Z., Zhang, H., Zeng, H., Huang, Q., Chen, Y., Jiang, W., Lin, Z., Qu, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000978 · Cited by 125
Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis
Bi, J., Liu, H., Cai, Z., Dong, W., Jiang, N., Yang, M., Huang, J., & Lin, T. (2018) · Aging · doi:10.18632/aging.101520 · Cited by 124
USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway
He, H., Yi, L., Zhang, B., Yan, B., Xiao, M., Ren, J., Zi, D., Zhu, L. W., Zhong, Z., Zhao, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.54442 · Cited by 123
Yang, Y., Wang, J., Huang, W., Wan, G., Xia, M., Chen, D., Zhang, Y., Wang, Y., Guo, F., Tan, J., et al. (2022) · Advanced Materials · doi:10.1002/adma.202203224 · Cited by 120
Davis, R. M., Kiss, B. M., Trivedi, D. R., Metzner, T. J., Liao, J. C., & Gambhir, S. S. (2018) · ACS Nano · doi:10.1021/acsnano.8b03217 · Cited by 119
de Oliveira, E. C. M., Caixeta, E. S., Santos, V. S. V., & Pereira, B. B. (2021) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2021.1898504 · Cited by 116
Wang, H., Mei, Y., Luo, C., Huang, Q., Wang, Z., Lu, G.-M., Qin, L., Sun, Z., Huang, C.-W., Yang, Z.-W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4796 · Cited by 116
Guarino, A., Polini, C., Forte, G., Favieri, F., Boncompagni, I., & Casagrande, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010209 · Cited by 106
Shan, G., Zhou, X., Gu, J., Zhou, D., Cheng, W., Wu, H., Wang, Y., Tang, T., & Wang, X. (2021) · Cellular Oncology · doi:10.1007/s13402-020-00500-0 · Cited by 114
Yu, L., Li, Z., Mei, H., Li, W., Chen, D., Liu, L., Zhang, Z., Sun, Y., Song, F., Chen, W., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1248 · Cited by 113
Vartolomei, M. D., Porav-Hodade, D., Ferro, M., Mathiéu, R., Abufaraj, M. M., Foerster, B., Kimura, S., & Shariat, S. F. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.05.014 · Cited by 119
Safiri, S., Kolahi, A., & Naghavi, M. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004128 · Cited by 113
Lin, Y., Lin, J., Wen, S.-I., Yang, S.-C., Tsai, T., Chen, H., Chou, K., & Hwang, T. I. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.01.004 · Cited by 111
Knapp, D. W., Dhawan, D., Ramos, J. A., Ratliff, T. L., Cresswell, G. M., Utturkar, S. M., Sommer, B. C., Fulkerson, C. M., & Hahn, N. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01493 · Cited by 108
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
